Literature DB >> 8862105

Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes.

F Vidal1, J Mensa, M Almela, J A Martínez, F Marco, C Casals, J M Gatell, E Soriano, M T Jimenez de Anta.   

Abstract

OBJECTIVE: To evaluate the trend in incidence of Pseudomonas aeruginosa bacteremia, underlying conditions of patients, mortality rate, and factors associated with poor outcome. PATIENTS AND METHODS: Medical charts of 189 consecutive episodes of P aeruginosa bacteremia, detected between January 1, 1991, and December 31, 1994, were prospectively evaluated. Associated risk factors, treatment, and outcome were recorded.
RESULTS: Pseudomonas aeruginosa bacteremia represented 5.7% of the total number of bacteremias, 6.9% of nosocomial bacteremias, and 23.6% of nosocomial gram-negative bacteremias. There were 1.5 episodes per 1000 discharges. These numbers were slightly lower than those recorded at our hospital 10 years earlier. Human immunodeficiency virus infection was the most frequent underlying disease (28/189 [15%]). Overall mortality was 18% (34/189). The presence of fatal underlying disease (P < .001), surgery (P = .001), pneumonia (P = .02), and severe sepsis (P < .001) were associated with poor prognosis, the mortality of the patients with these variables being 28%, 28%, 47%, and 62%, respectively. The presence of inappropriate definitive antimicrobial treatment became an independent factor predictive of death (P = .04) only when the subset of patients with intravenous catheter-associated bacteremia was excluded from the analysis. The survival rate was no greater in patients who received 2 or more antibiotics active in vitro against P aeruginosa than in those who received only 1. Neutropenia was not associated with increased mortality. The use of colony-stimulating factors did not affect the outcome of the neutropenic patients.
CONCLUSIONS: The rate of P aeruginosa bacteremia is falling slightly at our hospital. The emergence of the human immunodeficiency virus epidemic has had a considerable impact on both epidemiology and mortality. The presence of severe underlying disease, surgery, pneumonia, and, especially, severe sepsis are associated with a poor outcome. With the exclusion of patients with intravenous catheter-associated P aeruginosa bacteremia, the administration of an appropriate antimicrobial therapy is essential to a good outcome. Treatment with 1 active antibiotic seems to be sufficient.

Entities:  

Mesh:

Year:  1996        PMID: 8862105

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  67 in total

1.  Fluorescent In situ hybridization allows rapid identification of microorganisms in blood cultures.

Authors:  V A Kempf; K Trebesius; I B Autenrieth
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

2.  Rapid differentiation of fermentative from nonfermentative gram-negative bacilli in positive blood cultures by an impedance method.

Authors:  T C Chang; A H Huang
Journal:  J Clin Microbiol       Date:  2000-10       Impact factor: 5.948

3.  Colony-Stimulating Factors in the Therapeutic Approach to Sepsis.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-08       Impact factor: 3.725

4.  O-antigen serotypes and type III secretory toxins in clinical isolates of Pseudomonas aeruginosa.

Authors:  Karine Faure; David Shimabukuro; Temitayo Ajayi; Leonard R Allmond; Teiji Sawa; Jeanine P Wiener-Kronish
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

5.  Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia.

Authors:  Eric Chamot; Emmanuelle Boffi El Amari; Peter Rohner; Christian Van Delden
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

Review 6.  Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis.

Authors:  Mical Paul; Vered Shani; Eli Muchtar; Galia Kariv; Eyal Robenshtok; Leonard Leibovici
Journal:  Antimicrob Agents Chemother       Date:  2010-08-23       Impact factor: 5.191

7.  Evaluating ciprofloxacin dosing for Pseudomonas aeruginosa infection by using clinical outcome-based Monte Carlo simulations.

Authors:  Sheryl Zelenitsky; Robert Ariano; Godfrey Harding; Alan Forrest
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

8.  Population-based study of the epidemiology and the risk factors for Pseudomonas aeruginosa bloodstream infection.

Authors:  M D Parkins; D B Gregson; J D D Pitout; T Ross; K B Laupland
Journal:  Infection       Date:  2009-12-12       Impact factor: 3.553

9.  Controlling for severity of illness in outcome studies involving infectious diseases: impact of measurement at different time points.

Authors:  Kerri A Thom; Michelle D Shardell; Regina B Osih; Marin L Schweizer; Jon P Furuno; Eli N Perencevich; Jessina C McGregor; Anthony D Harris
Journal:  Infect Control Hosp Epidemiol       Date:  2008-11       Impact factor: 3.254

10.  ESBL and MBL in Cefepime Resistant Pseudomonas aeruginosa: An Update from a Rural Area in Northern India.

Authors:  Aarti Kotwal; Debasis Biswas; Barnali Kakati; Malvika Singh
Journal:  J Clin Diagn Res       Date:  2016-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.